IL157608A0 - New crystal forms of lamotrigine and processes for their preparations - Google Patents

New crystal forms of lamotrigine and processes for their preparations

Info

Publication number
IL157608A0
IL157608A0 IL15760802A IL15760802A IL157608A0 IL 157608 A0 IL157608 A0 IL 157608A0 IL 15760802 A IL15760802 A IL 15760802A IL 15760802 A IL15760802 A IL 15760802A IL 157608 A0 IL157608 A0 IL 157608A0
Authority
IL
Israel
Prior art keywords
lamotrigine
preparations
processes
crystal forms
new crystal
Prior art date
Application number
IL15760802A
Other languages
English (en)
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IL157608A0 publication Critical patent/IL157608A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
IL15760802A 2001-02-27 2002-02-27 New crystal forms of lamotrigine and processes for their preparations IL157608A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27168801P 2001-02-27 2001-02-27
PCT/US2002/006160 WO2002068398A1 (en) 2001-02-27 2002-02-27 New crystal forms of lamotrigine and processes for their preparations

Publications (1)

Publication Number Publication Date
IL157608A0 true IL157608A0 (en) 2004-03-28

Family

ID=23036634

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15760802A IL157608A0 (en) 2001-02-27 2002-02-27 New crystal forms of lamotrigine and processes for their preparations

Country Status (6)

Country Link
US (3) US6861426B2 (de)
EP (1) EP1390355A4 (de)
JP (1) JP2004526714A (de)
CA (1) CA2439468A1 (de)
IL (1) IL157608A0 (de)
WO (1) WO2002068398A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002068398A1 (en) * 2001-02-27 2002-09-06 Teva Pharmaceutical Industries Ltd. New crystal forms of lamotrigine and processes for their preparations
WO2003090693A2 (en) * 2002-04-23 2003-11-06 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing lamotrigine particles of defined morphology
EP1603889A1 (de) * 2003-03-17 2005-12-14 Hetero Drugs Limited Neue kristalline formen von lamotrigin
US7504516B2 (en) 2003-03-27 2009-03-17 Hetero Drugs Limited Crystalline forms of candesartan cilexetil
GB2395483A (en) * 2003-07-03 2004-05-26 Jubilant Organosys Ltd Crystalline lamotrigine and its monohydrate
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US20120142919A1 (en) * 2006-08-02 2012-06-07 Medichem, S.A. Method for synthesizing lamotrigine
US8486927B2 (en) 2007-11-09 2013-07-16 Thar Pharmaceuticals Crystalline forms of lamotrigine
CN114948868B (zh) * 2021-04-16 2023-04-14 上海奥科达医药科技股份有限公司 一种拉莫三嗪水合物的晶体形式、其制备方法及包含其的组合物
CN115068422B (zh) * 2022-08-19 2022-11-29 上海奥科达生物医药科技有限公司 一种拉莫三嗪湿混悬剂及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK153787C (da) * 1979-06-01 1989-01-16 Wellcome Found Analogifremgangsmaade til fremstilling af substituerede 3,5-diamino-6-phenyl-1,2,4-triaziner og alfa-cyanobenzyliden-aminoguanidinforbindelser til anvendelse som mellemprodukter herved
EP0021120B1 (de) * 1979-06-01 1983-04-06 The Wellcome Foundation Limited 3,5-Diamino-1,2,4-triazin-Derivate, Verfahren zur Herstellung dieser Verbindungen und pharmazeutische Zusammensetzungen sie enthaltend
ES8604019A1 (es) 1985-04-15 1986-01-16 Nippon Shinyaku Co Ltd Un procedimiento para preparar polvo fino de 2,5-dicloroben-zoguanamina y sus sales
GB8613183D0 (en) * 1986-05-30 1986-07-02 Wellcome Found Triazine salt
US5643591A (en) * 1991-01-16 1997-07-01 Fmc Corporation Solid dosage forms
GB9424766D0 (en) 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
GB9426448D0 (en) * 1994-12-30 1995-03-01 Wellcome Found Process
GB9512854D0 (en) 1995-06-23 1995-08-23 Wellcome Found Novel formulation
GB9518027D0 (en) * 1995-09-05 1995-11-08 Wellcome Found Pharmacologically active compound
US6525185B1 (en) * 1998-05-07 2003-02-25 Affymetrix, Inc. Polymorphisms associated with hypertension
CA2334937C (en) * 1998-12-14 2004-09-21 Torrent Pharmaceuticals Ltd. An improved process for the preparation of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
JP4919566B2 (ja) 1999-09-24 2012-04-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗ウイルス組成物
AU763244B2 (en) * 2000-01-03 2003-07-17 Rpg Life Sciences Limited A process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, commonly known as lamotrigine
EP1292582A1 (de) * 2000-06-08 2003-03-19 Merck & Co., Inc. 4-benzyl-2-hydroxy-1,4-oxazin-3-one und deren polymorphe formen
WO2002068398A1 (en) * 2001-02-27 2002-09-06 Teva Pharmaceutical Industries Ltd. New crystal forms of lamotrigine and processes for their preparations
US6482830B1 (en) * 2002-02-21 2002-11-19 Supergen, Inc. Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
CA2519779A1 (en) * 2003-03-26 2004-10-14 Teva Pharmaceutical Industries Ltd. A process for preparing a pharmaceutical active ingredient with high specific surface area

Also Published As

Publication number Publication date
CA2439468A1 (en) 2002-09-06
WO2002068398A1 (en) 2002-09-06
EP1390355A4 (de) 2005-02-23
US6861426B2 (en) 2005-03-01
US20030018030A1 (en) 2003-01-23
US7390807B2 (en) 2008-06-24
EP1390355A2 (de) 2004-02-25
JP2004526714A (ja) 2004-09-02
US20050171107A1 (en) 2005-08-04
US20080139808A1 (en) 2008-06-12
WO2002068398A9 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
HK1061075A1 (en) Eyeglasses and clasp for eyeglasses
GB0124299D0 (en) Crystal structure of enzyme and uses thereof
IL157577A0 (en) Disposable underpants and method of providing the same
IL158591A0 (en) Crystal forms of azithromycin
IL157142A0 (en) Modified antibodies and methods of use
GB0202633D0 (en) Stabilization of protein preparations
AU2002314466A1 (en) Withasol and methods of use
AU2002310099A1 (en) Identification of anti-protozoal agents
AU2002359512A1 (en) Belts and methods of use thereof
EP1405856A4 (de) Kristalle von oligosacchariden und verfahren zu deren herstellung
HK1083213A1 (en) Intermediates useful for the preparation of alpha-difluoromethyl ornithine (dfmo) and processes for preparation the same
EP1478748A4 (de) Fce-fusionsproteine zur behandlung von allergien und asthma
IL157608A0 (en) New crystal forms of lamotrigine and processes for their preparations
IL157351A0 (en) New crystal forms of oxcarbazepine and processes for their preparation
AU2002363938A8 (en) Methods and use of motoneuronotropic factors
IL163926A0 (en) Crystal structure of phosphodiesterase 5 and use thereof
AU2002240556A1 (en) New crystal forms of lamotrigine and processes for their preparations
EP1452597A4 (de) Verfahren zur aktivierung von protein
AU2002340437A1 (en) Crystals and structures of yiim proteins
EP1406921A4 (de) Hypoglykämische peptide und verfahren zu deren verwendung
IL161608A0 (en) Synthesis of 2-aralkoxyadenosines and 2-alkoxyadenosines
EP1392460A4 (de) Fluorwasserstoffe von aminosilanolen und ihre verwendung
GB0108287D0 (en) Methods of crystal optimisation
EP1435953A4 (de) Anti-vesicans-verbindungen und verfahren zu ihrer herstellung und verwendung
WO2003016502A9 (en) Tramdorins and methods of using tramdorins